AI Terminal
Achiko AG
Board/Management Information • Oct 7, 2022
804_rns_2022-10-07_b5922b73-d0c2-4a7b-9ad3-04c23963631a.html
Board/Management Information
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 7 October 2022 06:45
Achiko AG Appoints New Chief Financial Officer
Achiko AG / Key word(s): Miscellaneous
07-Oct-2022 / 06:45 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Achiko AG Appoints New Chief Financial Officer
Zurich, 7 October 2022: Ad hoc an n o u ncement pu r su a nt to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) a healthcare technology company that is developing new innovations and disruptive diagnostic solutions that put people first announced that it has appointed Lars Birkmann as Chief Financial Officer (CFO) as of 5 th October 2022, succeeding Adam O’Keeffe as ad interim CFO.
Mr Birkmann, 44, has successfully worked in the Swiss life sciences sector for over twenty years and has been involved in all areas of finance from accounting, financial control, treasury, and mergers and acquisitions. He will take over the CFO position at Achiko and join the Company’s Executive Committee. Prior to Achiko, Lars was the CFO at Ender Diagnostics AG (Bern) and before that the CFO for Sensile Medical AG (Olten).
Lars has completed his studies in Economics and Study in Law, and a degree in Business from the Business School in Leipzig. He is also a federal expert in European and Swiss VAT law.
“We are excited to welcome Lars on board”, said Mr Steven Goh, CEO of Achiko AG. “It’s the start of a process to build an executive team and Board with Swiss representation and is a decisive step towards the Company’s final transformation into becoming a diagnostics and technology company.”
ABOUT ACHIKO A G
Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com ) is developing disruptive diagnostic solutions that put people first. The Company’s lead product, AptameX ™, is a rapid, reliable Covid-19 test with a companion app, Teman Sehat ™, offering a user-friendly digital health passport. AptameX™ and Teman Sehat™ were launched in Indonesia in mid-2021 and AptameX™ received the CE Mark in the European Union in May 2022.
The AptameX™ DNA aptamer tests can be rapidly chemically synthesised, are cost-effective, easily scalable and have broad potential across multiple disease areas. Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field.
Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.
M edia contacts:
ACHIKO AG
Switzerland & Global
Marcus Balogh
Farner Consulting Ltd
T: +41 44 266 67 67
Disclaimer
This communi c a tio n expressl y or i m plicitly c o nta i ns certa i n f or w ard-look i ng s tatem e nts c o ncernin g A chik o A G an d it s business . Suc h stat e ment s in v olv e certai n k n o w n a n d un k no w n risks, uncer t ainties a n d othe r f actors, w hi c h coul d cause the actua l results, f i n ancial c o nditi o n, per f or m ance or achi e vement s o f A chik o A G to be material l y di ff erent f rom any f u t ure results, pe r f ormance or achiev e ments expressed or implie d by such f or w ard-l o oki n g statem e nts. A chiko A G is providing this com m uni c ati o n as o f this date and d oe s not u nder t ake to u p d ate a n y f or w ard- l ooki n g stat e ments contain e d herein as a result o f ne w in f ormat i on , future eve n ts or o ther w ise
End of Inside Information
| Language: | English |
| Company: | Achiko AG |
| Tessinerplatz 7 | |
| 8002 Zurich | |
| Switzerland | |
| E-mail: | [email protected] |
| Internet: | https://www.achiko.com/ |
| ISIN: | CH0522213468 |
| Valor: | 48788430 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1458663 |
| End of Announcement | EQS News Service |